Navigation Links
Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference
Date:1/24/2008

Conference will be held Feb. 11-13 at the Waldorf-Astoria Hotel in New York

City

NEW YORK, Jan. 24 /PRNewswire/ -- Gerson Lehrman Group (GLG) and the Biotechnology Industry Organization (BIO) today announced a collaborative agreement designed to strengthen the access to clinical information and insights at the tenth annual BIO CEO & Investor Conference.

"We're thrilled to have this unique partnership opportunity with BIO in their tireless efforts to increase the relevant and timely dissemination of some of the most highly technical and challenging scientific issues of today," said Alexander Saint-Amand, Chief Executive Officer of GLG. "Our company's long-standing mission is to empower decision-makers by connecting them to the academic and industry leaders driving innovation and productivity in our global economy."

Through this partnership, BIO will tap into GLG's network of experts from around the world in order to identify the most relevant thought leaders to discuss the latest issues and trends affecting drug development and clinical design in the biotechnology industry.

"Gerson Lehrman Group is an ideal partner for BIO's annual investment conferences with deep access to the clinical experts and investigators who can bring insights to pipeline research and current clinical practices," said James C. Greenwood, president and CEO of BIO. "Our Therapeutic Workshops and Business Roundtable discussions focus on educating investors and industry management on the issues that face product innovation, capitalization and commercialization."

The BIO CEO & Investor Conference is the largest independent biotechnology investor conference focused on publicly-traded companies. The conference features issue-oriented plenary sessions, educational sessions on therapeutic areas and business issues, company presentations, one-on-one meetings, and networking opportunities.

To see the latest updates on 2008 programming and speakers for BIO CEO & Investor Conference, please visit http://ceo.bio.org/opencms/ceo/2008/index.jsp.

About Gerson Lehrman Group

Gerson Lehrman Group (GLG) provides technology and services to support a marketplace for expertise. Since 1998, its platform for consultation and collaboration has helped the world's leading financial services firms, consultancies, corporations, and nonprofits find, engage, and manage experts in a broad range of industries and disciplines. GLG's unparalleled network of the world's leading expert consultants, known as the GLG Councils, includes more than 175,000 subject-matter experts who educate and provide insight to decision-makers through a wide range of consulting methods, including telephone consultations, expert surveys and seminars. GLG has invested in one of the world's most sophisticated infrastructures for expert recruiting and compliance. For more information about GLG, please visit http://www.glgroup.com.

About BIO and the Tenth Annual BIO CEO & Investor Conference

Now in its tenth year, the BIO CEO & Investor Conference is the largest independent biotechnology investor conference focused on publicly-traded companies. The conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities. The conference is hosted by the Biotechnology Industry Organization (BIO), representing more than 1,150 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO produces the BIO International Convention, the world's largest gathering of the biotechnology industry.

Contacts:

Gerson Lehrman Group

Margaret M. Molloy

212 880-6569

mmolloy@glgroup.com


'/>"/>
SOURCE Gerson Lehrman Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
2. Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network
3. Animal Protection Groups Condemn FDAs Endorsement of Animal Cloning
4. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
5. The Jordan Company, L.P. Has Teamed with the Management of Haas TCM Inc. to Form Haas TCM Group Inc.
6. Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference
7. Bioscience Group Warns Policymakers Against Complacency
8. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
9. Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei
10. The Ensign Group, Inc. Declares Quarterly Dividend of $0.04 Per Share
11. AG Mednet to Provide Image Network for Southwest Oncology Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):